

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051424 A1

(51) International Patent Classification⁷: **A61K 39/395**, (51/10, G01N 33/543, C07K 17/02

(21) International Application Number:
PCT/SE2004/001753

(22) International Filing Date:
26 November 2004 (26.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/525,703 28 November 2003 (28.11.2003) US
0303229-9 28 November 2003 (28.11.2003) SE

(71) Applicant (for all designated States except US): **MITRA MEDICAL AB [SE/SE]**; Ideon Research Park, S-223 70 Lund (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SANDBERG, Bengt, E. B. [SE/SE]**; Blomstergården 18, S-245 62 Hjärup (SE). **NILSSON, Rune [SE/SE]**; Annehemsvägen 29, S-226 48 Lund (SE).

(74) Agent: AWAPATENT AB; Box 5117, S-200 71 Malmö (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: TARGETING OF ERB ANTIGENS




Figure 1: Competitive inhibition of ¹¹¹In labelled 1033-trastuzumab binding to SKBR-3 cells by cold (unlabelled, without 1033-conjugate) trastuzumab.

WO 2005/051424 A1

(57) Abstract: A conjugate comprising a) a trifunctional cross-linking moiety, to which is coupled b) an affinity ligand via a linker 1, c) a cytotoxic agent, optionally via a linker 2, and d) an anti Erb antibody or variants thereof having the ability to bind to Erb antigens expressed on mammalian tumour surfaces with an affinity-binding constant of at least $5 \times 10^6 \text{ M}^{-1}$, wherein the affinity ligand is biotin, or a biotin derivative having essentially the same binding function to avidin or streptavidin as biotin, wherein stability towards enzymatic cleavage of the biotinamide bond has been introduced in linker 1.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.